Saffron (Crocus sativus L.) has attracted increasing interest as a nutraceutical option for depressive disorders, particularly for patients who experience incomplete response or poor tolerability with conventional treatments. Importantly, clinical studies have evaluated extracts derived from different plant parts, most commonly the stigma (the culinary “saffron” spice) and, in some trials, the petal, which have distinct constituent profiles and therefore differ in interpretability and generalisability. This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. Across placebo-controlled trials in mild-to-moderate depression, saffron, most commonly administered at 30 mg per day for approximately six weeks, has been associated with clinically meaningful reductions in depressive symptom severity, typically measured using the Hamilton Depression Rating Scale (HAM-D). Small head-to-head studies suggest broadly comparable short-term symptom improvement between saffron and standard antidepressants such as fluoxetine and imipramine, although these trials are generally underpowered and not designed to establish formal non-inferiority. Adjunctive studies, including trials of standardised extracts (e.g., Affron®) and constituent-focused interventions (notably crocin), provide preliminary support for augmentation in partial responders, but findings are heterogeneous and long-term outcomes remain unclear. Meta-analytic evidence generally indicates superiority over placebo and similar efficacy to selective serotonin reuptake inhibitors (SSRIs), with an overall favourable short-term tolerability profile; however, confidence is constrained by small sample sizes, restricted settings, variable product standardisation (including stigma versus petal preparations), and risk of bias/publication bias. Saffron’s putative antidepressant effects may involve modulation of monoaminergic pathways alongside antioxidant, anti-inflammatory, and neuroprotective actions. Current guidelines position saffron as a third-line complementary option for mild depressive episodes and as a potential adjunct in moderate depression. Overall, saffron appears promising for short-term symptom reduction in mild-to-moderate depression, but larger, longer, multi-centre trials using standardised preparations and clinically meaningful endpoints are required to clarify durability, comparative effectiveness, safety, and optimal clinical use.
Luigi Dimech (Tue,) studied this question.